Haemostatix

Haemostatix is developing first-in-class topical clotting agents for the treatment of bleeding. The technology is based on a novel class of molecule that binds directly to fibrinogen to promote haemostasis. The lead candidate PeproStat, an ultra-fast topical haemostat addressing a $1bn market globally. Albion sold its stake in Haemostatix to Ergomed in May 2016.

New class of coagulant gets go ahead for clinical trial
HAEMOSTATIX - NEW CLASS OF COAGULANT GETS GO AHEAD FOR CLINICAL TRIAL
Christoph Ruedig
VCTs